CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

SUBMISSION OF CLINICAL STUDY APPLICATION TO THE CENTER FOR DRUG EVALUATION FOR THE GROUP'S HEPATITIS C DRUG "SOFOSBUVIR TABLET"

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries (the "**Group**")) announces that "Sofosbuvir Tablet" (the "**Drug**") developed by the Group has completed all pre-clinical study and application for clinical study has been submitted to the Center for Drug Evaluation of the State Food and Drug Administration of the People's Republic of China (the "**PRC**") (File no.: CXHL1401645 JI).

Sofosbuvir is a new drug for the treatment of chronic hepatitis C ("**Hep C**") developed by a U.S. pharmaceutical company (the "**U.S. Drug Co**"), and was approved for sales in the United States by the U.S. Food and Drug Administration in December 2013, and approved for sales in the European Union countries by the European Medicines Agency in January 2014.

Sofosbuvir is a drug with new effect target and new effect mechanism, and is the world's first NS5B polymerase inhibitor for the treatment of Hep C. Currently, there is no drug with the same effect mechanism on the market. It is also the first drug that does not require combination with interferon for the safe and effective treatment of certain genotypes of Hep C. It has been proven in clinical trials that: in respect of genotypes 1 and 4 Hep C, the Drug in combination with peg-interferon alfa and ribavirin achieved an overall sustained virologic response ("**SVR**") of 90%; in respect of genotype 2 Hep C, the Drug in combination with ribavirin achieved a SVR of 89%-95%; in respect of genotype 3 Hep C, the Drug in combination with ribavirin achieved a SVR of 61%-63%, with a significant reduction in the period of treatment. It is worth to note that some Hep C patients with cirrhosis were also enrolled in the clinical study of sofosbuvir.

According to the information announced by the U.S. Drug Co, the Drug has recorded a sales of US$5.75 billion in the first half of 2014, and the market expects sofosbuvir will quickly become a blockbuster drug.

At present, Sofosbuvir Tablet is neither approved for import in the PRC nor approved for production by any domestic enterprise yet. The Group will strive its best to become the first company in the PRC to obtain the approval for selling Sofosbuvir Tablet in order to benefit Hep C patients in the PRC.

By order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 17 November 2014

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. FENG Zhenying, Mr. CHAK Kin Man, Mr. PAN Weidong, Mr. ZHAO John Huan, Mr. WANG Shunlong, Mr. WANG Huaiyu, Mr. LU Jianmin, Mr. WANG Zhenguo and Mr. WANG Jinxu as executive Directors; Mr. LEE Ka Sze, Carmelo as non-executive Director and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Shilin as independent non-executive Directors.